HEPH Hollis-Eden Pharmaceuticals (MM)

Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today presented additional positive interim data from its on-going Phase I/II clinical trial with its investigational oral drug candidate TRIOLEX� (HE3286) in obese insulin resistant subjects at the 6th World Congress on Insulin Resistance Syndrome, being held September 25th � 27th in Los Angeles, California. Dr. Jaime Flores-Riveros, Vice President, Endocrinology and Metabolism at Hollis-Eden Pharmaceuticals, presented the data. The additional data extend findings previously reported in a corporate symposium held in conjunction with the 68th Scientific Sessions of the American Diabetes Association demonstrating that TRIOLEX is safe and well tolerated to date, and that it significantly improved insulin sensitivity and lowered fasting blood glucose and insulin levels in obese insulin resistant subjects treated orally with 5 or 10 milligrams of the compound administered twice daily for 28 days, as compared to placebo-treated subjects. Dr. Flores-Riveros presented additional data showing that insulin resistant subjects (as defined by a physiological index of glucose disposal or M-value less than 5), displayed a significantly exacerbated inflammatory response characterized by higher levels of the pro-inflammatory cytokines MCP-1, TNF-alpha, IL-6 and IL-1beta produced in LPS stimulated peripheral blood mononuclear cells (PBMC) from these patients. In contrast to more insulin sensitive subjects (M>5), treatment of these insulin resistant subjects (M